$2.79
0.72% yesterday
Nasdaq, May 20, 10:02 pm CET
ISIN
US00091E1091
Symbol
ABSI

Absci Corp Stock price

$2.79
-0.28 9.12% 1M
+0.11 4.10% 6M
+0.17 6.49% YTD
-1.82 39.48% 1Y
-0.71 20.29% 3Y
-13.21 82.56% 5Y
-13.21 82.56% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.02 0.72%
ISIN
US00091E1091
Symbol
ABSI
Sector
Industry

Key metrics

Market capitalization $355.89m
Enterprise Value $214.75m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 44.55
P/S ratio (TTM) P/S ratio 73.84
P/B ratio (TTM) P/B ratio 1.79
Revenue growth (TTM) Revenue growth -9.95%
Revenue (TTM) Revenue $4.82m
EBIT (operating result TTM) EBIT $-113.12m
Free Cash Flow (TTM) Free Cash Flow $-76.81m
Cash position $150.06m
EPS (TTM) EPS $-0.93
P/E forward negative
P/S forward 33.87
EV/Sales forward 20.44
Short interest 20.98%
Show more

Is Absci Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Absci Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Absci Corp forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Absci Corp forecast:

Buy
100%

Financial data from Absci Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4.82 4.82
10% 10%
100%
- Direct Costs 13 13
6% 6%
271%
-8.23 -8.23
4% 4%
-171%
- Selling and Administrative Expenses 24 24
3% 3%
495%
- Research and Development Expense 68 68
44% 44%
1,411%
-100 -100
27% 27%
-2,076%
- Depreciation and Amortization 13 13
6% 6%
271%
EBIT (Operating Income) EBIT -113 -113
22% 22%
-2,347%
Net Profit -107 -107
2% 2%
-2,230%

In millions USD.

Don't miss a Thing! We will send you all news about Absci Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Absci Corp Stock News

Neutral
GlobeNewsWire
about 16 hours ago
VANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will be participating in the following upcoming investor conferences.
Neutral
Seeking Alpha
7 days ago
Absci Corporation (NASDAQ:ABSI ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and Chief Executive Officer Zach Jonasson - Chief Financial Officer and Chief Business Officer Christian Stegmann - Senior Vice President of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Securities Bren...
Neutral
GlobeNewsWire
7 days ago
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into ...
More Absci Corp News

Company Profile

AbSci Corp. engages in the development of protein biomanufacturing technology. It offers SoluPro, an all-in-one protein expression platform which produces complex proteins using simplest and least expensive organism. The company was founded by Sean Mcclain and Mark Valasek in 2011 and is headquartered in Vancouver, WA.

Head office United States
CEO Sean McClain
Employees 157
Founded 2011
Website www.absci.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today